40
- iTunes U Neurology part 1 Seattle Pacific University
- iTunes U Neurology part 2 Seattle Pacific University
- iTunes U Neurology part 3 Seattle Pacific University
Headache
- SIGN qrg 107 Headache Nov 08
- eguidlines Headache diagnosis
- ruralhealthwest april 2001 headaches
- Medication Overuse Headache NeLM / North West Medical Information Centre
- Primary Care MRI in investigation of headache
Headache Red Flags
- Present on waking
- Worse on coughing or bending over
- Localised
- Sudden onset
- Associated with other symptoms:
- visual, especially in elderly
- nausea
- weakness
- numbness, pins and needles
- inco-ordination
Tension headache |
---|
Tight band-like headache encircling the head with tense scalp neck and shoulder girdle muscles.
Chronic Tension headache >15 days /m. |
Analgesic headache |
---|
Due to regular use/overuse > 15 days per month over last 3 months of simple analgesics NSAIDS opiates and triptans.Often worse first thing in the morning and exacerbated by exercise.Symptoms resolve after withdrawal (cold turkey or gradual tapering) |
Medication Overuse Headache DTB 2010;48:2 |
Exercise headache |
---|
Ice pick headache |
---|
Migraine |
---|
Migraines and cluster headaches are benign vascular headaches involving the constriction and dilation of intra cranial arteriesClassic migraine starts with an aura (migraine with aura) – usually visual (zig zags of light) but sometimes involve visual or speech disturbances, strange smell, and flashes of lights.The aura may occur in isolation but is usually followed within an hour by a severe abrupt onset throbbing unilateral headache which later becomes more generalized and may be incapacitating for hours. Nausea, vomiting,sensitivity to light, and noise is often present.The migraine may be triggered by cheese alcohol OCP periods caffeine anxiety and travel in 50% of patients.Migraines can also occur without the preceding aura (common migraine). |
Cluster Headache |
---|
Excrutiating sudden onset headache typically occurring daily in the early hours of the morning more frequently in males occurring in clusters lasting 6-8 weeksRare more common in smokers. The most common type of cluster headache is the episodic type, in which extremely intense, strictly unilateral pain develops around one eye, often at night; attacks can come on daily or even several times a day, and last for 30 minutes to 2 hours. There is often associated lacrimation of the affected eye, which may be reddened; and nasal symptoms, such as blocked nose. Ptosis may also be present. These episodes can occur at regular intervals for a period of 6-12 weeks at a time, typicallyonce every year or 2 years, often at the same time of year for many years or even decades.There is a chronic form of cluster headache, in which there is no remission of pain between the clusters of headache, and a continuous milder background headache can develop that is present in-between attacks. Verapamil is often used as prophylaxis for patients with cluster headache and triptans may be helpful during an acute attack. |
Migraine diagnosis (BASH)
At least five episodes of a headache lasting 4-72 hours, with at least of two of the following four features:
- 1 Unilateral
- 2 Pulsating quality (varies with the heartbeat)
- 3 Moderate or severe intensity of pain
- 4 Aggravated by exercise.
In addition, the patient must experience nausea/vomiting and/or photophobia/phonophobia during the attack.
Auras typically occur 5-50 minutes before the headache and are visual, consisting of transient hemianopic disturbance or a spreading scotoma. There may also be focal neurological symptoms. Patients with prolonged auras should be referred for further investigation.
Migraine treatments | |
---|---|
Simple analgesia | eg soluble ibuprofen (400-600 mg), aspirin (600-900 mg) or paracetamol. taken analgesia asap after symptoms start |
Nausea | If the patient complains of nausea, a prokinetic anti-emetic such as prochlorperazine (3 mg buccal tablet), domperidone (20 mg) or metoclopramide (10 mg) can be added; these help by increasing gastric emptying |
Rectal analgesia | Rectal administration of diclofenac (100 mg) and domperidone (30 mg) may be more effective than oral medication; this should be tried as a second-line therapy. |
Triptans | If these measures fail, consider a triptan. Patients respond differently to the various triptans on offer, and if there is no response with the first one tried, it is worth changing formulation (eg to a nasal spray) or trying another triptan.Patients should be advised to take the triptan as soon as possible after the headache symptoms start but not until then, ie not during the aura. For all triptans except zolmitriptan, another dose should not be taken for the same migraine. If the migraine recurs however, then another dose can be taken, after an interval of at least 2 hours.If an oral triptan is prescribed, a concomitant anti-emetic should be considered.Oral sumatriptan at a dose of 50 mg is often used as a first choice. The nasal spray offers no real advantage over oral medication if vomiting is a problem, as absorption will still be reduced. Sumatriptan also comes as a subcutaneous injection; this is particularly useful if a rapid effect is required.Other appropriate choices include zolmitriptan 2.5 mg, either as a tablet or as Zomig Rapimelt®, an orodispersible tablet that is placed on the tongue and allowed to disperse, then swallowed. Zolmitriptan is licensed for adolescents.Rizatriptan, 10-mg tablets or wafers, is useful if stronger treatment is required. Rizatriptan interacts with propranolol and in this case the dose should be reduced to 5 mg.Almotriptan and eletriptan are still being evaluated in terms of their exact role in migraine management. Frovatriptan is the longest acting triptan on the market. Naratriptan has a relatively low efficacy and is most useful for patients who have significant adverse reactions to other triptans and in patients with frequent relapses.Some patients find it beneficial to be given more than one type of triptan; for example, sumatriptan tablets and a zolmitriptan nasal spray. That way, if the tablet does not work for a particular migraine, the nasal spray can be tried. |
Migraine prophylaxis |
---|
If the patient is getting frequent migraines that have an adverse effect on their lifestyle (eg more than four per month), it is then reasonable to considerprescribing a regular prophylactic medication for a period of about 4-6 months. The prophylactic medication can then be slowly tapered off over 2-3 weeks.Beta-blockers such as propranolol or atenolol are usually the first choice unless there is a specific contraindication. The patient commonly starts with a very low dose of beta-blocker, eg 10 mg bd of propranolol, and then gradually has it titrated upwards until it has the desired effect. If one betablocker does not work, it is worth trying another. The patient should take the drug at an optimum dose for 1 month before treatment failure can be established. It is probably preferable to choose a relatively cardioselective beta-blocker initially, to minimise side-effects (eg atenolol 25 mg bd).Amitriptyline 10-150 mg nocte is particularly useful when the migraine coexists with tension-type headaches, chronic pain conditions or insomnia.Again start at a low dose and titrate upwards.Amitriptyline does not have a licence for migraine prophylaxis.Valproate 300-1000 mg bd is sometimes used as a second-line prophylactic treatment, but is contraindicated in pregnancy or when pregnancy is a possibility. Again, it is not licensed for migraine prophylaxis.Pizotifen is also sometimes used, usually starting at a dose of 0.5 mg taken at night (it has a sedative action). Weight gain and increased appetite are common side-effects. It can be increased in increments of 0.5 mg every week until the patient is on 1.5 mg. Evidence for its efficacy is lacking, however, and it should not be used as a first-line treatment.Verapamil is particularly good as prophylaxis for cluster headaches.Feverfew is an option for patients who want to try a herbal alternative; it can be used at doses of 50-143 mg per day in adults. The primary care migraine guidelines (available at www.eguidelines.co.uk) state that herbal remedies should not be used alone, but only to complement conventional treatment.If these measures do not work, there are other possibilities such as methysergide, which is highly effective but is associated with serious side-effects, including retroperitoneal fibrosis; for this reason, it should be initiated by a specialist. |
Menstrual migraine |
---|
Attacks of migraine (without aura) that occur regularly around the onset of menstruation and at no other time. It is worth suggestinga trial of an NSAID at regular intervals for the duration of the menstrual period (eg mefenamic acid 500 mg tds-qds). Other options are estradiol gel (1.5 mg in 2.5 g) applied daily from day 3 for 7 days (no added progestogens are needed if the woman has regular cycles), the COCP or cerazette® (to inhibit ovulation). These measures should be tried for at least three cycles |
Idiopathic intracranial hypertension |
---|
Hypertension and Pregnancy |
---|
Conditions of pregnancy such as pre-eclampsia and eclampsia may also cause severe headaches. Additional symptoms to look for with pre-eclampsia or eclampsia arerapid weight gain, oedema, and hypertension. If this is left untreated, it can lead to toxemia of pregnancy with development of seizures, hypertensive crisis, or fetal and or maternal death. |
Temporal arteritis (neurology) |
---|
Rx Prednisolone 40-60mg/day stat. Maintainance 7.5-10mg/day. May need 1-2 years. |
Infections |
---|
Life threatening -meningitis, encephalitis or brain abscess.Headaches are also common complaint associated with everyday infections |
Meningitis |
---|
Caused by bacterial, viral or fungal infection, blood or tumour iniltration.Cardinal symptoms are fever, headache , photophobia, neck stiffness. Papilloedema is a late sign. |
Encephalitis |
---|
inflammation of the brain itself. Presents with headache preceded by odd behaviour and fits prior to collapse. May be viral esp HSV |
Head Injury |
---|
Consider in all patients presenting with severe headaches and or neurological changes following a recent history of trauma. |
SubduralCollection of blood between brain surface (arachnoid membrane) and the dura due to tearing of the bridging veins particularly in rapid acceleration/decelleration injuries.
|
SAH |
---|
|
http://www.bbc.co.uk/news/uk-england-17368824 |
CVA and TIA | |
---|---|
amaurosis fugax | transient loss of vision “like a curtain coming down” due to embolus from internal carotid to opthalmic artery |
TIA | Focal neurological symptoms lasting <24hrs |
Cresendo TIAs | Increased in frequency duration and severity of TIAs. Due to critical stenosis pof internal carotid or carotid dissection. |
Stroke | Rapid non-transient neurological deficit from cerebrovascular injury.Focal or global impairement of CNs function developing rapidly and lasting >24hrs. |
see also in CVS |
Carotid artery Disease
Atheromatous plaque at common carotid bifurcation or its branches. Causes stroke or blindness by thrombosis, reduced flow or embolisation.
Stroke Acute Management
FAST stroke recognition | |
---|---|
Face | Has their face fallen on one side? Can they smile? |
Arms | Can they raise both arms and keep them there? |
Speech | Is their speech slurred? Ask patient to repeat a sentence |
Time | to call 999 if you see any single one of these signs. |
Cincinnati prehospial stroke scale | |
---|---|
Facial Droop | Ask patient to smile |
Arm Drift | ask patient to close eyes and hold out both for 10 secs |
Speech | Ask patient to repeat ” The sky is blue over Cincinnati |
Stroke ABCD2 |
---|
Age > 60 1 point |
BP > 140 systolic or > 90 diastolic 1 point |
Clinical Features
|
Duration of symptoms
|
Diabetes
|
Risk assessment score for urgency of referral after CVA/TUIA |
Score >4 or 2 or more TIAs in 1w (crescendo TIAs) or on warfarin — patient at high risk of further stroke: refer immediately |
Score <4 or presenting >1w after symptoms resolve — patient at low risk of a further stroke — refer within 1w |
All patients with TIA should be given aspirin 300mg immediately and then daily until reviewed in TIA clinic. Normally the dose is stepped down to 75mg after two weeks. Secondary prevention medications are started prior to discharge. Don’t forget they should not drive in the first month – see DVLA guidance.
Stroke Classification by pathology | |
---|---|
Ischaemic (85%) |
|
Haemorrhagic (15%) |
|
Stroke classification by location | |
---|---|
Site | Signs & Symptoms |
Anterior Cerebral Artery | lower limb weakness (motor cortex) confusion (frontal lobe) |
MCA | facial weakness and hemiparesis, hemisensory loss, apraxia, neglect, dysphasia, quadrantopia |
Posterior Cerebral Artery | Hemianopia |
Internal Carotid Artery | |
Vertebral/Basilar Artery | Cranial nerve pathologies + LOC |
Stroke syndromes | territory supplied by | clinical syndrome |
---|---|---|
total anterior circulation infarction TACI | middle cerebral artery MCA | |
partial anterior circulation infarction PACI | branches of MCA or isolated anterior cerebral artery occlusion | |
posterior circulation infarction POCI | infarction of brainstem cerebellum or occipital lobe | |
lacunar infarct LACI | occlusion of basal perforating arteries |
Hemiplegia
Stroke primary prevention | |
---|---|
Lifestyle factors | Healthy diet, alcohol, exercise and smoking cessation advice and treatment. |
BP | Maintaining a normal BP. |
Lipids | If CVD> 20% consider a statin using a ‘fire and forget’ approach (Simvastatin 40mg od)If known IHD then lipid management decreases the risk of stoke (Audit standard Cholesterol < 5.0 and LDL < 2.5 BUT aspirational target = Cholesterol < 4.0 and LDL < 2.0). ‘Treat to target’ as per hyperlipidaemia guidelines. |
ACE | n known IHD, Peripheral Vascular Disease (PVD) or DM with 1 risk factor e.g. smoking or dyslipidaemia in patients aged over 55 then consider using a Ramipril starter regime and aim to work the dose up to10mg a day. |
Anticoagulants Antiplatelets | All patients with valvular heart disease and AF should be considered for warfarin. Only use the CHAD score to determine anticoagulation use in patients with non valvular AF. |
Stroke secondary prevention | |
---|---|
Lifestyle factors | Healthy diet, alcohol, exercise and smoking cessation advice and treatment.Annual review should check BMI, smoking status/cessation advice, alcohol intake, BP and bloods |
BP | BP should be maintained at <130/<80 (unless they have bilateral coronary artery stenosis). The audit standard is <150/<90. |
Anticoagulants Antiplatelets | Aspirin – all patients with a history of ischaemic stroke should be on low dose aspirin, as this reduces CVS mortality and recurrent stroke.Patient’s with TIA or stroke benefit from Aspirin & Dipyridamole for 2 years and then revert to aspirin alone – Esprit study. |
Statins | All patients with a history of ischaemic stroke irrespective of age, sex or cholesterol level should commence a statin to achieve a minimum audit standard of Cholesterol < 5.0 and LDL < 2.5 BUT the aspirational target = Cholesterol < 4.0 and LDL < 2.0mmol/l. Start with an adequate dose e.g. Simvastatin 40mg. Warn the patient about common side or serious side effects e.g. myalgia. Check fasting lipids and ALT at 4 weeks. Uptitrate the dose if not at target (e.g. Simvatsatin 40, then Simvastatin 80, then Atorvastatin 40mg) and repeat lipids in another 4 weeks. Once at target they only need annual review. |
ACEI | ACE inhibitors Ramipril 10 mg a day in stoke patients > 55 years decreases CVD deaths and recurrent stroke – HOPE trial. |
Endarterectomy | All patients with non disabling stroke or TIA should be considered for urgent specialist assessment – patients with high grade ipsilateral stenosis benefit from carotid endarterectomy. |
almost all ischaemic stroke and TIA survivors should be taking low dose aspirin, an ACE inhibitor, another antihypertensive and a statinAlmost all stroke/TIA patients will benefit from treatment statins and blood pressure medication regardless of actual levels plus aspirin + AF (source Red House Bradford?) |
UMN LMN | UMN | LMN |
---|---|---|
Power | reduced | reduced |
Tone | increased – spastic paralysis | decreased – flaccid paralysis |
Wasting | only if lack of use prolonged | yes |
Reflexes | increased | decreased or absent |
Clonus | yes | no |
Plantars | extensor | flexor |
Aphasias | |||
---|---|---|---|
Broca’s / Expressive | motor association cortex of frontal lobe | good | non-fluent dysarthric agrammatical |
Wernicke’s / Receptive | posterior temporal lobe | poor | fluent grammatical meaningless |
Conduction | arcuate fasciculus | good | fluent grammatical |
Global | substantial language area | poor | very little |
Broca’s | BROKen aphasia-broken speech |
Wernicke’s | Wordy aphasia- wordy, but making no sense |
Dysarthrias and Speech Disorders | |
---|---|
Staccato speech | cerebellar disease |
Scanning speech | combination of cerebellar and pyramidal disease eg MS or phenytoin overdose |
EEP Infopoems Aug 2011 Screening tool for dysphagia after stroke
Bulbar palsy pseudubulbar palsy | |
---|---|
Bulbar palsy |
|
Pseudobulbar palsy |
|
Brainstem lesions
Top Of Midbrain
Pontomedullary Junction
Lateral medullary lesions
Weakness and Clumsiness
Ataxia | |
---|---|
Clumsy uncoordinarted movements due to poor postural control due to to cerebellar or sensory nerve (posterior column) disease. | |
Gait ataxia | incoordination when walking |
Cerebellar ataxia | Patients with cerebellar lesions fall to the side of the lesion – if asked to walk in circles will walk in ever decreasing or ever increasing circles. |
Truncal ataxia | tendancy to fall backwards whilst sitting or standing – suggests midline cerebellar lesions. |
Friedericks ataxia | AD spinocerebellar disorder presenting in childhood or adolescence. Associated with pes cavus, pes equinovarus, and kyphoscoliosis. |
Ataxia telangiectasia | rare inherited disorder with nystagmus, conjunctival and skin telangiectasia. |
Posterior Column Dysfunction
Rombergs Sign |
---|
|
youtu.be/fNasho7u0hM |
Gait Abnormalities |
---|
Gait Analysis |
Tremor inc Benign Essential | |
---|---|
Physiological | “physiological” – fine tremor. Similar tremor found in anxiety, hyperthyroidism and alcoholism. |
Benign essential | Sightly larger amplitude. More common in elderly. Worse on movementRelieved by alcohol and by propranolol (eg 10-40 mg bd) often bilateral. |
Parkinsonian | Coarse (4-7 Hz) resting pill-rolling tremor – unaffected by alcohol or betablockers -usually unilateral onset |
Intention | increases in amplitude as the hand reaches the target – with overshooting/past-pointing – demonstrated by finger-nose and nose-examiner’s finger testing – suggests cerebellar disease. |
Titubation | vertical nodding tremor of head when sitting or standing in some patients with cerebellar disease especially patients with MS |
Flapping | asterixis – liver failure, Wenickes encephalopathy, uraemia, hypercapnia, CCF. Denonstrated with arms outstretched and hands dorsiflexed |
Hysterical | |
neurology.org Oct 2011 Tremor |
Bells Palsy | |
---|---|
idiopathic isolated LMN lesion of the facial nerve | |
Solitary, unilateral facial nerve paralysis (including forehead) causing drooping of the mouth, loss of nasolabial fold loss of forehead furrowing and difficulty closing eyes smiling blowing out cheeks an whistlingA lower motor neurone lesion causes weakness of all the muscles of facial expression. The angle of the mouth falls. Weakness of frontalis occurs, and eye closure is weak.Associated symptoms—Patients with Bell’s palsy commonly feel pain in or behind the ear. Numbness can occur on the affected side of the face. Loss of taste on the ipsilateral anterior two thirds of the tongue is common. Hyperacusis due to stapedius paralysisBells phenomenon – eyeball rols up but lids remain open when attempting to close the eye. | |
CVA | |
CVA causes UMN and sparing the upper half of the face – blinking, eye closure and frontalis not affected – patients would usually have ipsilatera hemiparesis +/- speech difficultiesWith an upper motor neurone lesion frontalis is spared, normal furrowing of the brow is preserved, and eye closure and blinking are not affected.Check that no other cranial nerves are involved. | |
Treatment | |
Oral prednisolone and aciclovir in patients with moderate to severe palsy, ideally within 72 hours but up to seven days from onset of symptoms. Prednisolone should be prescribed at a dosage of 1 mg/kg/day (maximum 80 mg daily) for the first week, with the dosage tapering off over the second week. Exclude R_H first (see below)Aciclovir may be given (800 mg five times a day for five days)Eye protection – taping, protective glasses, artificial tears. | |
Prognosis | |
90% recover within 2-12w. Aberrrant reinnervation may occur. |
Causes of facial nerve palsy | |
---|---|
Bell’s palsy | idiopathic LMN facial nerve palsy – diagnosis of exclusion. Normal looking ear. Pure tone audiogram is required. Acycolvir 400mg + steroids 60mg OD for 5 days. Pts reviewed in clinic after one week. Eye protection at night. |
Ramsey-Hunt | Rapid onset, pain, vesicles in ear canal, pinna + sometimes soft palate If it involves 8th nerve ?Hearing loss +vertigoLook also for a painful rash over the ear, which indicates Ramsay Hunt syndrome caused by herpes zoster virus.and any presence of rash that may indicate herpes zoster. |
Supporative OM | Distinguish from serous otitismedia by the presence of purulent fluid in the middle ear.IV abx + nasal decongestants. No clinical improvement after 24-48 hrs emergency myringotomy |
Nerve compression | 2ndry to compression or dehiscence of nerve |
Trauma | Palsy present in 20% of longitudinal + 80% transverse temporal bone fractures. Look for CSF otorrhoea or rhinorrhoea. Ix: Fine cut axial CT scan |
other DD otitis-mastoiditis, multiple sclerosis, trauma, parotid tumor, acoustic neuroma sarcoidosis (may cause bilateral LMN lesion) Lyme disease |
Facial Nerve Palsy -House-Brackmann grading | |
---|---|
Grade1 | Normal |
Grade2 | Slight weakness, good eye closure with minimal effort |
Grade3 | Obvious weakness, complete eye closure, strong but asymmetrical mouth |
Grade4 | |
Grade5 | Motion barely perceptible, incomplete eye closure, slight movement of corner of mouth |
Grade6 | No movement |
Cranial Nerve Palsies
http://hacking-medschool.com/cranial-nerves
Horners |
---|
|
Causes
|
(see also Opthalmology for these sections below) |
Ptosis |
---|
Drooping of upper eylelid which normally covers only 1/6 of the cornea.may be unilateral or bilateral, partial or complete with or without overaction of frontalisCauses
|
Oculomotor palsies
CN 3 palsy |
---|
|
Causes
|
youtu.be/fMAIYqPNiYY |
CN 4 palsy |
---|
CN 6 palsy |
---|
Paralysis of lateral rectus hence medial deviation of affected eye (convergent squint) due to unopposed action of medial rectus with diplopia inability to move laterally on testing. |
Causes
|
youtu.be/3M1GhgV8px0 |
Cerebellar dysfunction |
---|
|
Tests of cerebellar function
|
Cerebellar tumours
Posterior fossa lesions
CNS infections (neurology)
- CNS infections msevans.com (schroll down)
- CNS infections Nervous System Diseases.com
- hacking-medschool/abs-cns
Meningitis (neurology)
- 250textbooks/meningitis-emergencies
- 250textbooks/meningitis-vaccination
- 250textbooks/meningitis-infections
Encephalitis
Inflammation of brain substance, most commonly due to viral infection (HSV, HZ, mumps…).
Meningitis like picture +/- drowsiness/behavioural changes/confusion/seizures.
Fits faints funny turns blackouts
Dizzyness & Vertigo see ENT
Syncope see Cardiology
- Syncope = transient LOC with loss of postural tone
- Mechanical fall = coming to land on the ground with no LOC
Epilepsy |
---|
Seizure = paroxysmal synchronised cortical electrical discharge. |
Siezure Types |
---|
Partial – localised
|
Simple Partial – does not affect conciousness |
Complex Partial – affects conciousness |
Generalised
|
Abscence (petit mal) |
Clonic |
Tonic |
Tonic Clonic(grand mal, major motor) |
Atonic |
Akinetic |
Febrile |
Status Epilepticus |
Focal Seizures | |
---|---|
Frontal lobe Motor Seizures | Motor convulsions Jacksonian March Todds paralysis |
TLE | aura and hallucinations |
Frontal Lobe complex partial seizure | LOC automatisms rapid recovery |
Rapid Medicine Sam & Teo W-B |
Generalised Seizures | |
---|---|
Tonic ClonicGrand Mal | aura– generalised spasm (tonic) –repetitive synchronous jerks (clonic) +/- incontinence tongue biting — post ictal |
Absencepetit mal | LOC but upright posture maintained– staring into space blinkingor other repetitive movement –immediate recovery |
Non convulsive status epilepticus | Acute confusional state |
Rapid Medicine Sam & Teo W-B |
Patients with suspected epilepsy should be referred to a specialist as soon as possible, ideally within 2 weeks (NICE 2004).
Treatment is generally recommended after a second seizure. However, it may be instigated by a specialist after the first seizure if the patient has a neurological deficit, the EEG shows definite epileptic activity, brain imaging is abnormal, or if the patient is unable to accept the possibility that they may experience a second seizure.
Epilepsy and QOF
hacking-medschool/qof/epilepsy
Epilepsy Rx
Monitoring epilepsy Rx
Blood levels are only necessary in the following circumstances:
To determine compliance with treatment
If there is suspected toxicity
If the dose of phenytoin needs to be adjusted
If there is concern about interaction with other medications
New-onset liver or kidney failure.
NICE recommends that all patients on enzyme-inducing drugs (carbamazepine, topiramate, oxcarbazepine, phenytoin and phenobarbital) should have routine bloods done every 2-5 years, including full blood count (FBC), urea and electrolytes (U&Es), liver function tests (LFTs), vitamin B12 levels and calcium.
Stopping Epilepsy Rx
The longer a patient has been seizure-free on treatment, the better their prognosis.
The following factors increase the risk of relapse on withdrawal of medication:
- Age of onset of epilepsy >16 years
- Being on more than one anti-epileptic medication
- History of seizures while taking medication
- History of tonic-clonic or myoclonic seizures
- Abnormal EEG.
After 5 years of being seizure-free, a patient with one or two of the above risk factors has approximately a 20-30% risk of recurrent seizures on withdrawal of the medication (compared to a 10-15% risk if they continue taking it).
After 10 years of being seizure-free, this risk drops to about 10% (or 5% if they continue taking the medication). The risk of a recurrent seizure is highest 9 months after withdrawal of treatment.
Anti-epileptic medication needs to be tapered off gradually over 2-3 months, usually under the supervision of a specialist. Only one medication should be stopped at a time.
Epilepsy and contraception
superceded by the above guidelines
For women taking hepatic enzyme-inducing anti-epileptic drugs – carbamazepine, topiramate, oxcarbazepine, phenytoin and phenobarbital:
The progesterone-only pill is not recommended.
The progesterone implant is not recommended either.
If the combined oral contraceptive pill is used, at a minimum initial dose of 50 micrograms. oestrogen is recommended. ‘Tricycling’ might be necessary if the woman experiences breakthrough bleeding.
If the depot progesterone method is preferred, injections need to be given at intervals of 10 weeks instead of 12 weeks.
Women on anti-epileptic drugs should be advised that the doses of levonorgestrel used for emergency contraception need to be increased to 1.5 mg and 750 micrograms taken 12 hours apart.
Parkinson’s disease |
---|
Common neurological disease of older people due to progressive degeneration of dopaminergic neurones axon terminals of cells projecting from substantia nigra to caudate nucleus and putamen (extrapyramidal system)Prevalence 160/100 000, 2% over 80s, annual incidence 13/100 000 total numbers 100 000 |
Presents with
Slowness and poverty of emotional and voluntary movement, rigidity and tremor. Early signs are loss of facial expression (mask-like facies) , general ‘slowing down’ of movements and unilateral loss of arm swing. Fatiguing occurs with repetitive movements such as opening and closing the hand, pronating and supinating the wrist or tapping the heel on the ground. |
|
Presents with
Slowness and poverty of emotional and voluntary movement, rigidity and tremor. Early signs are loss of facial expression (mask-like facies) , general ‘slowing down’ of movements and unilateral loss of arm swing. Fatiguing occurs with repetitive movements such as opening and closing the hand, pronating and supinating the wrist or tapping the heel on the ground. |
Parkinsons syndrome (Parkinsonism) |
---|
|
Parkinsons guidelines *** | |
---|---|
Goal of therapy is to reduce symptoms, functional impairment and effect on patients lifeTreatment considerations are complex and therapy should be initiated or altered by a SpecialistTherapy is usually initiated with ldopa, monoamine oxidase type-B inhibitors, selegiline or dopamine agonists.Excessive daytime sleepiness and sudden onset of sleep can occur with levodopa and dopamine receptor agonists.Patients starting treatment with these drugs should be warned of the possibility of these effects.Patients who have suffered excessive sedation or sudden onset of sleep, should refrain from driving or operating machines until these effects have stopped recurring.Warned patients about the potential for dopamine agonists, and less commonly levodopa to cause impulse control disorders such as pathological gambling, binge eating and hypersexuality.
Older patients are more susceptible to adverse drug effects and treatment should be initiated at low doses and increased with caution. |
|
l-dopa carbidoparelieves symptoms in most patients, but long-term use is associated with motor complications such as involuntary movements (dyskinesia), as well as a shortened response to each dose (wearing-off phenomenon) and unpredictable ‘on-off’ fluctuations. | |
L-dopa plus dopa decarboxolase inhibitor | l-dopa carbidoparisk of motor side effects over time |
L-dopa plus dopa decarboxolase inhibitor | l-dopa carbidoparisk of motor side effects over time |
Dopamine agonists |
monotherapy or adjuncts to l-dopa less likely to cause dyskinesia first-line in younger patients without serious co-morbidities |
MAOI B inhibitors | selegilineUsing a dopamine agonist or selegiline initially may reduce the need for ldopa |
COMT inhibitors | entacapone |
|
L-dopa preparations |
|||
---|---|---|---|
Initiate at low dose and increase gradually to minimise side effects. Adjust Dosage, timing and frequency to suit individual patient needs | |||
Co-beneldopa Madopar | |||
Name | levodopa | benserazide | carbidopa |
Madopar 62.5 | 50mg | 12.5mg | – |
Madopar 125 | 100mg | 25mg | – |
Madopar 250 | 200mg | 50mg | – |
Madopar dispersible 62.5 | 50mg | 12.5mg | – |
Madopar dispersible 125 | 100mg | 25mg | – |
Madopar CR 125 | 100mg | 25mg | – |
Co-careldopa Sinemet | |||
Name | levodopa | benserazide | carbidopa |
Sinemet 62.5 | 50mg | – | 12.5mg |
Sinemet 110 tabsCo-careldopa 10/100 | 100mg | – | 10mg |
Sinemet Plus Co-careldopa 25/100 | 100mg | – | 25mg |
Sinemet 275Co-careldopa 25/250 | 250mg | – | 25mg |
Half Sinemet CR | 100mg | – | 25mg |
Sinemet CR | 200mg | – | 50mg |
Drugs and doses |
---|
Co-beneldopa (Madopar®)Dose: Expressed as levodopa, initially 50mg 3-4 times daily, increase by 100mg once or twice weekly according to response; usual maintenance dose 400 – 800mg daily in divided doses after meals. Elderly: initially 50mg once or twice daily, increased by 50mg daily every 3-4 days according to response. |
Co-careldopa (Sinemet®)Dose: Expressed as levodopa, initially 100mg 3 times daily, increased by 50-100mg daily or on alternate days according to response, up to 800mg daily in divided doses after food. |
Note: Please refer to BNF for advice on dosage when transferring patients from immediate-release levodopa preparations to modified release preparations.The total daily dose of carbidopa should be at least 70mg. A lower dose may not achieve full inhibition of peripheral dopa-decarboxylase, resulting in an increase in adverse effects.Nausea and vomiting due to co-beneldopa or co-careldopa may be reduced by taking doses after food. Vomiting can be controlled with domperidone in a dose of 10-20mg three times daily, see section 4.6. Levodopa should not be withdrawn abruptly. Patients should be warned that levodopa might colour urine dark red.Dispersible co-benelopa may be useful for patients with swallowing difficulties or where rapid absorption is desired, for example first thing in the morning. Modified release preparations are not recommended for initiation of therapy, they may help with ‘end-of- dose’ deterioration or nocturnal immobility and rigidity. |
Dopamine receptor agonistsDopamine receptor agonists may be considered for patients with early Parkinson’s disease and motor symptoms or for the management of complications in patients with advanced Parkinson’s disease, either used alone or as an adjunct to levodopa with dopa-decarboxylase inhibitor. |
ROPINIROLE or PRAMIPEXOLERopinirole (as hydrochloride) tablets 250micrograms, 500micrograms, 1mg, 2mg, 5mg; 28-day starter pack of 42x250microgram (white) tablets, 42x500microgram (yellow) tablets, 21x1mg (green) tablets; 28-day follow-on pack of 42x500microgram (yellow) tablets, 42x1mg (green) tablets, 63x2mg (pink) tabletsDose: Initially 750micrograms daily in 3 divided doses, increased by increments of 750micrograms at weekly intervals to 3mg daily; further increased by increments of up to 3mg at weekly intervals according to response; usual range 9-16mg daily; maximum 24mg daily. Note – when administered as an adjunct to levodopa, concurrent dose of levodopa may be reduced by approx. 20%.Prolonged release ropinirole tablets (Requip® XL ?) are only licensed for patients with established adequate symptomatic control on immediate release (standard) ropinirole, they may be prescribed under the direction of a specialist. Substitution of ropinirole prolonged release tablets for ropinirole immediate release tablets should be supervised by an appropriate specialist in Parkinson’s disease.Pramipexole tablets 88micrograms, 180micrograms, 350micrograms, 700microgramsNote: Doses and strengths are stated in terms of pramipexole (base); equivalent strengths in terms of pramipexole dihydrochloride monohydrate (salt) are as follows:88micrograms base ? 125micrograms salt; 180micrograms base ? 250micrograms salt; 350micrograms base ? 500micrograms salt; 700micrograms base ? 1mg saltDose: Initially 88micrograms 3 times daily, dose doubled every 5-7 days if tolerated to 350micrograms 3 times daily; further increased if necessary by 180micrograms 3 times daily at weekly intervals; maximum 3.3mg daily in 3 divided doses.Prolonged release pramipexole tablets (Mirapexin® Prolonged Release) may be prescribed under the direction of a specialist in patients for whom the use of pramipexole is appropriate, to provide the benefit of once daily dosing at an equivalent cost.Rotigotine transdermal patch (Neupro® ?) may be prescribed under the direction of the Neurology Clinic or Geriatric Medicine for either advanced Parkinson’s disease in combination with levodopa, when transdermal administration would facilitate treatment or for early stage idiopathic Parkinson’s disease as monotherapy in patients with swallowing difficulties or poor compliance. Patches require storage in a refrigerator.Dopamine receptor agonists may cause nausea and vomiting; patients can be treated with domperidone at a dose of 10-20mg three times daily, see section 4.6.Dopamine receptor agonists are associated with more neuropsychiatric side effects than levodopa and can cause hypotensive reactions and postural hypotension. When used as adjunctive therapy, dopamine receptor agonists can exacerbate levodopa-induced adverse effects.Ergot-derived dopamine receptor agonists, bromocriptine, cabergoline, and pergolide, have been associated with pulmonary, retroperitoneal, and pericardial fibrotic reactions and require regular clinical monitoring. See MHRA Drug Safety Update, October 2008 for further information. They should not be used as first line treatment for Parkinson’s disease and are only initiated on specialist advice. |
Monoamine-oxidase-B inhibitors |
Selegiline hydrochloride tablets 5mg, 10mg, liquid 10mg/5mL, oral lyophilisates (freeze-dried tablets) 1.25mg (Zelapar®)Dose: Conventional tablet/liquid, 10mg in the morning or 5mg at breakfast and midday. Zelapar®, initially 1.25mg daily before tablet should be placed on the tongue and allowed to dissolve.Selegiline, a monoamine-oxidase-B inhibitor, may be used in advanced Parkinson’s disease in conjunction with levodopa to reduce ‘end-of-dose’ deterioration. Patients with early Parkinson’s disease and motor symptoms may also be considered for treatment. In trials of patients with early Parkinson’s disease early treatment with selegiline delayed the need for levodopa therapy. Selegiline also has a levodopa sparing effect when given simultaneously with levodopa associated with a reduction in motor fluctuations but not dyskinesias. Selegiline oral lyophilisates (Zelapar®) is a buccal formulation that avoids first-pass metabolism. It may be considered in patients unable to tolerate the conventional tablets. |
Catechol-0-methyltransferase inhibitors |
Entacapone tablets 200mgDose: 200mg with each dose of levodopa with dopa-decarboxylase inhibitor; maximum dose 2g daily.Entacapone, a catechol-O-methyltransferase inhibitor, may be used in advanced Parkinson’s disease in conjunction with levodopa to reduce ‘end-of-dose’ deterioration. For patients stabilized on co-careldopa and entacapone, a combination product, Stalevo® may be suitable. |
Co-careldopa with entacapone Stalevo | |||
---|---|---|---|
Max 10 tablets daily (7 for Stavelo 200/50/200)1 tablet to be taken for each dose, to limit the amount of entacapone taken | |||
Stavelo | levodopa | carbidopa | entacapone |
50/12.5/200 | 50mg | 12.5mg | 200mg |
75/18.75/200 | 75mg | 18.75mg | 200mg |
100/25/200 | 100mg | 25mg | 200mg |
125/31.25/200 | 125mg | 31.25mg | 200mg |
Stalevo150/37.5/200 | 150mg | 37.5mg | 200mg |
200/50/200 | 200mg | 50mg | 200mg |
Antimuscarinic drugs |
---|
used for extra-pyramidal side effects not be used as first line treatmentless effective than dopaminergic drugs and associated with neuropsychiatric and cognitive adverse effects. They should therefore not be given to patients with comorbidities such as cognitive impairment or significant psychiatric illness. They should also be avoided in older patients due to their adverse effects. Abrupt withdrawal of antimuscarinics should be avoided. |
Procyclidine or orphenadrine may occasionally be useful in patients with tremor unresponsive to other drugs, on the advice of a specialist. They may also reduce Parkinsonian symptoms induced by antipsychotic drugs.in patients with Parkinson’s disease as they are |
Restless leg syndrome |
---|
|
Cramps |
---|
Multiple sclerosis MS |
---|
Episodic autoimmune inflammatory disorder affecting myelinated nerves (white matter) within the brain and spinal cord and leading to scarring (sclerosis).Usually starts in early adulthood. Attacks/ lesions are disseminated in time and place. |
Relapsing/remitting MSSymptoms come and go. Periods of good health or remission are followed by sudden symptoms or relapses (80% of people at onset) |
Secondary progressive MSFollows on from relapsing/remitting MS. There are gradually more or worsening symptoms with fewer remissions (about 50% of those with relapsing/remitting MS develop secondary progressive MS during the first 10 years of their illness) |
Primary progressive MSFrom the beginning, symptoms gradually develop and worsen over time (10–15% of people at onset)Between three and seven people per 100 000 population are diagnosed with MS each year and about 100 to 120 people per 100 000 population have MS. From these rates it is estimated that in England and Wales about 1800 to 3400 people are newly diagnosed with MS each year and that 52 000 to 62 000 people have MS |
|
Motor neurone disease MND |
---|
|
Chorea |
---|
|
Huntingtons chorea |
---|
AD degenerative disease of Basal gangia causing progressive dementia with abnormal quasi-purpuseful rapid jerking movements affecting face tongue and distal extremities. |
Hemiballismus |
---|
Involuntary one sided rapid violent flinging from full extension to abduction or internal rotation due to lesion of subthalmic nucleus. |
Myaesthenia Gravis |
---|
? neuromuscular junction dysfunction.? tensilon® test: 2mg I.V. ? repeat 4mg X 2 prn ? have atropine ready.Myasthenic crises ? inadequate dose of medication, too much medication, refractory to meds, orinfection/stress/trauma.L ABC’s, atropine prn, Solu-cortef® prn, withhold meds prn until the tensilon® test is positive, and treat theprecipitating cause, e.g. UTI.? unlike myasthenia gravis and botulism, with the Lambert-Eaton syndrome, the hand grip strengthincreases with repetition, the so-called upwards staircase phenomenon (may occur with Ca of the lung). |
GBS Guillian Barré syndrome |
---|
Acute ascending peripheral neuropathy |
|
Tick Paralysis |
---|
Syringomyelia |
---|
Neurofibromatosis |
---|
AD inherited disorder affecting neural crest cells. |
Type 1 Von Recklinghausens – spinal and cutaneous neurofibromas
|
Type 2 Schwanommas |
Paraesthesia and Numbness
Pins and Needles in the Hand
Peripheral Neuropathy
Investigating peripheral neuropathy BMJ 2010
- Peripheral neuropathy ABCDE
- Alcohol
- B12
- CRF and carcinoma
- Diabetes and drugs
- Every vasculitis
Mononeuritis multiplex |
---|
Mononeuritis Multiplex SCALD
|
4 |
Polyneuropathies
iTunes U Polyneuropathies Rock Valley College
Radiculopathy
Peripheral nerves
Peripheral nerve lesions
Ulnar palsy – claw hand
C7/8/T1 supplies
flexor carpi ulnaris – ulnar flexion of hand
flexor digitorum profundus (medial fibres) – flexion of distal phalanx of ring and little fingers
adductor pollicicis – Froments test – weakness causes flexion of distal phalanx when attempting to hold onto piece of paper between thumb and clenched fist.
abductor digiti minimi – abduction of little finger
opponens digiti minimi – opposition of little finger
flexor digiti minimi – flexion of little finger –
interossei (dorsal and palmar) and 3rd 4th lumbricals – flexion of prox phalanx, extension of distal and middle phalanx, (P)adduction and (D)abduction
(ie all the intrinsic muscles of the hand except 3 muscles of the thenar eminence APB OP FPB and the 3rd and 4th lumbricals)
Cutaneous sensation to ulnar border of hand on dorsal and palmar aspects, little finger and ulnar half of ring finger
May be damaged by fractures around the elbow or lacerations to forearm or wrist.Ulnar lesion below elbow produces clawing of 4th and 5th fingers (due to overextension of MCPs and flexion of the IPs due to unopposed action of long flexors an extensors) with slight separation of ring and little fingers and wasting of small muscles.
Causes
Injury/tethering around olecranon groove.
If bilateral – sryngomyelia, MND, cervical spondylosis, cervical cord tumours
Wrist Drop – Radial Nerve
C5 6 7 8 supplies
Triceps and anconues – forearm extension
Brachioradialis – forearm flexion
Extensor Carpiradialis – radial extension of hand
Extensor digitorum – extension of phlanges of all 4 fingers
Extensor digiti minimi – extension of phlanges of little finger
Extensor carpi ulnaris – unar extension of hand
Supinator – supination of forearm
Abductor pollicis longus – abduction of metacarpal of thumb
Extensor pollicis brevis – extension of thumb
Extensor digitorum longus – extension of index finger
Due to fracture of humerus involving spiral groove.
Lesion causes wrist drop due to weakness of triceps, ECR, ED and EPL. Patient unable to extend the wrist, fingers at MCP joints and the thumb.
Sensory loss to posterior aspect of thumb and dorsoradial side of hand + posterior aspect of forearm in higher lesions
(may in fact be minimal due to overlap from median and ulnar territories)
Median Nerve Palsy
C678 T1 supplies
Pronator teres – probation of forearm
Flexor carpi radialis – radial flexion of hand
Palmaris longus – flexion of hand
Flexor digitorum superficialis – flexion of middle phalanx of all 4 fingers
Flexor pollicis longus – flexion of terminal phlanx of thumb
Flexor digitorum profundus – flexion of terminal phalanx of index and middle fingers
Lateral lumbricals – flexion of prox phalanx and extension of middle and distal phlanges of index and middle finger
Opponens pollicis – opposition of metacarpal of thumb
Abductor pollicis brevis -abduction of metacarpal of thumb – straight raise thumb vertically with back of hand on table.
Flexor pollicis brevis – flexion of proximal phalanx of thumb
Cutanous senstion to volar aspect of thumb, index and middle fingers
Lesions cause wasting of the thenar eminence with thumb falling in a flat simian position
Foot drop
Damage to common peroneal or lateral popliteal nerve where it winds round head of the fibula.
Autonomic neuropathy
Myopathies
Myopathies American College of Rheumatology
Charcot Marie Tooth CMT HMSN PMA |
---|
Relatively common (1 in 2500) group of inherited (AD) neurological disorders affecting mainly motor (and sensory) peripheral nerves causing causing weakness and atrophy of peroneal muscles of calf leading to inverted champagne bottle appearance. and small muscles of feet causing claw foot (pes cavus) Due to segmental demyelination of peripheral nerves with associated degeneration of the nerve axons and anterior horn cells.Reflexes are diminished and sensation mildly affected.Pes Cavus = high arched foot = increased height of dorsal longitutudinal arch with dorsal contracture of MTP joints – most commonly occurs in isolation but may be associated with neurological conditions – PMA, Friederichs sryngomyelia spina bifida.aka hereditary motor and sensory neuropathy HMSN or peroneal muscular atrophy PMA |
ninds article |
Myotonic dystrophy |
---|
Autosomal dominant. condition presenting in adult life with muscular dystrophy (wasting and weakness) and myotonia (abnormal sustained contraction)Features: wasting of head and neck muscles esp sternal heads of sternomastoid, bilateral ptosis,cataracts, frontal balding, distal muscle weakness especially forearms, testicular atrophy. |
Atrophy AD |
Baldness |
Cataracts Chromosome 9 |
Droopy eyes Dysphagia Diabetes |
EF expressionless face or forehead – wasting of muscles of facial expression |
Gonadal atrophy (small pituitary fossa) |
Heart – cardiomyopathy conduction defect |
Immunology low serum Ig intellectual deterioration |
Fascioscapulohumeral dystrophy |
---|
|
CNS tumours | |
---|---|
Meningioma | Commonest |
Astrocytoma | Fibrillary (cerebrum) or pilocytic ( cerebellum and brainstem) |
Gioblastoma multiforme | High-grade invasive tumour |
Haemangioblastoma | Vascular tumour often in cerebellum |
Pituitary adenoma | benign. Space occupying and endocrine effects |
Oligodendroglioma | 10% gliomas. Epileptiform. |
Medulloblastoma | Invasive midline cerebellar tumour in children |
Ependymoma | Bening tumour of spinal cord and 4th ventricle |
lymphoma | In immunosuprresed. Highly malignant. |
|
Presentation
Headache, vomitting , fits, peronality changes, focal neurological defects, false localising signs
Localising syndromes | |
---|---|
Olfactory grove | anosmia frontal lobe dysfunction |
Caverous sinus | Squint (CN 3,4,6) V1/V2 sensory loss |
Foster Kennedy (sphenoid meningioma) | CN2 compression with ipsilateral optic atropy and papilloedema |
Pituitary fossa | Bitaemporal hemianopia (optic chiasm compression from suprasellar extension), hypopituitarism or hypersecretion syndromes |
Parinaud’s Syndrome (pineal) | Impaired upgaze (superior midbrain lesion) or obstructive hydrocephalus (3rd ventricle) |
Parasagittal region | Spastic pararparesis mimicking cord compression |
Cerebellopontine | Unilateral deafness facial weakness then unilateral ataxia nad hemifacial sensory impairement |
Rapid Medicine Sam & Teo – Wiley Blackwell |